Dasatinib Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your dasatinib prescription or have heard about shortages affecting other leukemia medications, you may be wondering: is dasatinib actually in shortage in 2026? The short answer is no—dasatinib does not have an active listing on the FDA Drug Shortage database as of 2026. But access problems are real, and patients need to understand why.

Is Dasatinib on the FDA Drug Shortage List in 2026?

No. The FDA Drug Shortage database lists medications where supply cannot meet demand at the manufacturer or distributor level. As of early 2026, dasatinib (Sprycel and generics) is not on that list. Generic versions are manufactured by multiple companies—including Apotex, Teva, Lupin, Zydus, and Dr. Reddy's—providing a diversified supply chain that makes a true industry-wide shortage unlikely.

Why Are Patients Still Having Trouble Getting Dasatinib?

Even without an FDA-declared shortage, dasatinib access problems are real and frustrating. The core issue is that dasatinib is a specialty oncology drug—it is not distributed through the same supply chain as common retail drugs. Here are the main reasons patients experience delays:

• Specialty pharmacy-only distribution: Standard retail pharmacies don't stock it. Patients must navigate specialty pharmacy networks tied to their insurance plan.
• Insurance prior authorization: Nearly every insurance plan requires prior authorization for dasatinib, and this process can take days to weeks.
• Step therapy requirements: Some insurers require patients to try a less expensive TKI (like generic imatinib) before approving dasatinib, even when the prescriber believes dasatinib is the most appropriate choice.
• High cost as a practical barrier: Full retail price can exceed $20,000–$27,000 per month. Without insurance or copay assistance, patients may be unable to afford it even if it's available.

Has the Generic Version Improved Access?

Yes, meaningfully so. Generic dasatinib is now available from multiple manufacturers, and discount programs like GoodRx have brought the cash price down to approximately $824–$891 per 30-day supply for 100 mg tablets. For self-pay patients or those with high insurance copays, the generic combined with a coupon has opened up access that didn't exist when only brand Sprycel was available.

However, generic dasatinib is still classified as a specialty drug and is not routinely stocked at every pharmacy that participates in GoodRx. Patients using coupons should call ahead to verify that the pharmacy has the specific strength they need.

What Patients Should Do to Protect Their Treatment in 2026

Given the specialty pharmacy access landscape, here are the most important steps you can take to keep your dasatinib treatment uninterrupted:

1. Refill early: Begin your refill request 10–14 days before you run out. Specialty pharmacy processing takes time.
2. Know your specialty pharmacy: Confirm which specialty pharmacy your insurance requires and build a relationship with them. Save the pharmacist's direct phone number.
3. Enroll in a patient assistance program: BMS Access Support (Sprycel) and the Apotex Instant Savings Program can reduce your out-of-pocket costs significantly. Some patients pay $0 per month with these programs.
4. Appeal insurance denials promptly: If your insurance denies coverage, work with your oncologist to file an expedited appeal. Most insurers must respond to urgent appeals within 72 hours.
5. Contact your oncology team immediately: If you're at risk of running out, call your oncologist's office the same day. They may have medication samples or can contact the manufacturer for emergency bridge supply.

What About Dasatinib and the Broader TKI Landscape in 2026?

The CML treatment landscape is well-supported. With five approved first-line TKIs (imatinib, dasatinib, bosutinib, nilotinib, and asciminib) and several third-line options, patients today have more choices than ever. If dasatinib becomes unavailable for any reason, your oncologist has alternative options to keep your CML under control. The key is not to wait until you've run out—proactive communication with your care team is everything.

How medfinder Can Help

If you're unsure whether a specialty pharmacy near you has your dasatinib in stock, medfinder contacts pharmacies on your behalf and texts you which ones can fill your prescription. For more tips, read our guide on how to find dasatinib in stock near you.